• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma

by | Oct 14, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells

by | Oct 9, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma

by | Oct 8, 2024 | Myeloma News

Source: Pharmacy Times articles This marks India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. Read More

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

by | Oct 8, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Transplant in myeloma: individualized approaches needed depending on context, access and biology

by | Oct 6, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor

by | Oct 4, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT